Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial
Dorosti M, Jafary Heidarloo A, Bakhshimoghaddam F, Alizadeh M
The British journal of nutrition · 61 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
- Intake measured by
- Not stated
Who paid for it
- Funding
- Independent funding
- University or hospital
- Urmia University
- University or hospital
- Urmia University of Medical Sciences
Based on 2 listed funder(s).
Publication
- Published
- 2019-11-05 · Br J Nutr · vol. 123 · issue 3 · pp. 328–336
- Publisher
- Cambridge University Press
- Cited
- 73 citations · more than 93% of similar papers · 3.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 37 works
- Access
- Free to read
- Research areas
- Liver Disease Diagnosis and Treatment · Diet, Metabolism, and Disease · Food composition and properties
- Keywords
- Medicine, Fatty liver, Steatosis, Internal medicine, Gastroenterology, Triglyceride, Blood pressure, Anthropometry, Disease, Cholesterol
- MeSH
- liver, humans, gamma-glutamyltransferase, alanine transaminase, aspartate aminotransferases, treatment outcome, eating, adult, middle aged, female, male, non-alcoholic fatty liver disease, edible grain, whole grains
4 authors
From IR
- Masoumeh DorostiUrmia University; Urmia University of Medical Sciences
- Ali Jafary HeidarlooImam Khomeini Hospital; Urmia University; Urmia University of Medical Sciences
- Farnush BakhshimoghaddamUrmia University; Urmia University of Medical Sciences
- Mohammad Alizadeh · correspondingUrmia University; Urmia University of Medical Sciences
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a considerable challenge to public health across the globe. Whole grain is highly recommended as an inseparable part of a healthy diet and has been proposed as an effective way to manage NAFLD. The objective in the present study was to evaluate the effects of whole-grain consumption on hepatic steatosis and liver enzymes as primary outcomes in patients with NAFLD. Over the 12 weeks of this open-label, randomised controlled clinical trial, 112 patients (mean age 43 (sd 8·7) years; BMI 32·2 (sd 4·3) kg/m2) were randomly assigned to two groups to receive dietary advice, either to obtain at least half of their cereal servings each day from whole-grain foods or from usual cereals. By the end of the study, the grades of NAFLD showed a significant decrease in the intervention group (P < 0·001). In addition, a significant reduction in serum concentration of alanine aminotransferase (P < 0·001), aspartate aminotransferase (P < 0·001), γ-glutamyltransferase (P = 0·009), systolic blood pressure (P = 0·004) and diastolic blood pressure (P = 0·008) was observed in the intervention group compared with the control group. After adjusting, however, no significant differences were found between the two groups in terms of lipid profile, glycaemic status and anthropometric measurements. Overall, our study demonstrated that consumption of whole grains for 12 weeks had beneficial effects on hepatic steatosis and liver enzymes concentrations in patients with NAFLD.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.